500.com Limited to Hold Annual General Meeting on December 25, 2020

PR Newswire

SHENZHEN, China, Nov. 23, 2020 /PRNewswire/ — 500.com Limited (NYSE: WBAI) (“500.com” or the “Company”), an online sports lottery service provider in China, today announced that it will hold its annual general meeting of shareholders at 12F, West Side, Block B, Building No. 7, Shenzhen Bay Eco-Technology Park, Nanshan District, Shenzhen, The People’s Republic of China on December 25, 2020 at 10:00 a.m., Beijing / Hong Kong Time.

Holders of record of ordinary shares of the Company at the close of business on November 25, 2020, US Eastern time (the “Record Date”) are entitled to notice of, and to attend and vote at, the annual general meeting or any adjournment thereof. Holders of the Company’s American Depositary Shares (“ADSs”) who wish to exercise their voting rights for the underlying ordinary shares must act through the depositary of the Company’s ADS program, Deutsche Bank Trust Company Americas.

The notice of the annual general meeting, which sets forth the resolutions to be submitted to shareholder approval at the annual general meeting is available on the Investor Relations section of the Company’s website at http://ir.500.com.

About 500.com Limited

500.com Limited (NYSE: WBAI) is a leading online sports lottery service provider in China. The Company offers a comprehensive and integrated suite of online lottery services, information, user tools and virtual community venues to its users. 500.com was among the first companies to provide online lottery services in China and is one of two entities that have been approved by the Ministry of Finance to provide online lottery sales services on behalf of the China Sports Lottery Administration Center, which is the government authority that is in charge of the issuance and sale of sports lottery products in China.

Safe Harbor Statements

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “going forward,” “outlook” and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

For more information, please contact:

500.com Limited

[email protected]

Christensen

In China
Mr. Eric Yuan
Phone: +86-10-5900-1548
Email: [email protected]

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/500com-limited-to-hold-annual-general-meeting-on-december-25-2020-301178707.html

SOURCE 500.com Limited

Exact Sciences to participate in December investor conference

PR Newswire

MADISON, Wis., Nov. 23, 2020 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast.

  • Evercore ISI HealthCONx Conference
    Fireside Chat on Wednesday, December 2, 2020, at 1:00 p.m. EST

The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.

About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company’s website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, expectations, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, the anticipated results of our product development efforts, the anticipated benefits of the pending acquisition of Thrive Earlier Detection Corporation (“Thrive”), including estimated synergies and other financial impacts, and the expected timing of completion of the transaction. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible effects on our operations, including our supply chain, and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the success of our efforts to facilitate patient access to Cologuard via telehealth; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; the amount and nature of competition for our products and services; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Society of Clinical Oncology, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services and assess potential market opportunities; our ability to effectively enter into and utilize strategic partnerships, such as through our Promotion Agreement with Pfizer, Inc., and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability, and the ability of Thrive, to maintain regulatory approvals and comply with applicable regulations; our ability to manage an international business and our expectations regarding our international expansion and opportunities; the potential effects of foreign currency exchange rate fluctuations and our efforts to hedge such effects; the possibility that the anticipated benefits from our business acquisitions (including the pending acquisition of Thrive and recent acquisition of Base Genomics Limited (“Base”) cannot be realized in full or at all or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of acquired businesses’ operations will be greater than expected and the possibility of disruptions to our business during integration efforts and strain on management time and resources; the outcome of any litigation, government investigations, enforcement actions or other legal proceedings; our and Thrive’s ability to receive the required the required regulatory approvals for the pending merger and to satisfy the conditions to the closing of the transaction on a timely basis or at all; the occurrence of events that may give rise to a right of one or both of us and Thrive to terminate the merger agreement; possible negative effects of the consummation of business acquisition on our acquired companies’ respective businesses, financial conditions, results of operations and financial performance; significant transaction costs and/or unknown liabilities; risks associated with potential transaction-related litigation; our and Thrive’s ability to retain and hire key personnel; and the other risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:

Megan Jones

Exact Sciences Corp.
[email protected]
608-535-8815

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/exact-sciences-to-participate-in-december-investor-conference-301178586.html

SOURCE EXACT SCIENCES CORP

KBR Charity Golf Tournament Raises Over $530k, Gives Back to COVID-19 Frontline Workers

PR Newswire

HOUSTON, Nov. 23, 2020 /PRNewswire/ — KBR (NYSE: KBR) announced today it has raised more than $532,000 for nine local and national charities at its fourteenth annual charity golf tournament. Since 2007, the tournament has raised over $6.5 million for worthy nonprofit organizations that align with KBR’s charitable focus areas of health, education and safety.

This year’s socially distanced tournament benefitted a diverse group of organizations that are making a real difference with a special focus on health care workers and first responders on the frontlines in the fight against COVID-19. In addition, the tournament supported other organizations whose missions are focused on keeping communities safe, preserving the environment and supporting veterans. This year’s charitable recipients are:

  • St. Jude Children’s Research Hospital
  • Houston Fire Department
  • Houston Police Department
  • Buffalo Bayou Partnership
  • Galveston Bay Foundation
  • Impact a Hero
  • The Chester Pitts Charitable Foundation
  • Houston Methodist Hospital Foundation
  • Memorial Hermann Foundation

“In these times, it’s especially important that we give back to our communities,” said Stuart Bradie, KBR President and CEO. “KBR is contributing $250,000 directly to front line workers that have sacrificed so much for our communities this year, and we’re honored to stand shoulder to shoulder with these men and women.”

Bradie continued, “KBR’s young professionals always make the Charity Golf Tournament a tremendous success and this year is no different. 2020 has been challenging in so many ways, so it means a great deal to me, and to KBR, that we were able to move forward with this event and I am especially proud of the work our team put in to ensuring the safety of each participant.” 

The 14th annual tournament was held on Thursday, November 19, 2020 at Kingwood Country Club in Kingwood, Texas and featured extensive safety guidelines including a virtual auction and awards.

For more information about the tournament, visit charitygolf.kbr.com or by searching #KBRCharityGolf on any of KBR’s social media pages.

About KBR

KBR is a global provider of differentiated professional services and solutions across the asset and program life cycle within the government and technology sectors. KBR employs approximately 28,000 people worldwide with customers in more than 80 countries and operations in 40 countries.

KBR is proud to work with its customers across the globe to provide technology, value-added services, and long- term operations and maintenance services to ensure consistent delivery with predictable results. At KBR, We Deliver.

Visit www.kbr.com  

Forward Looking Statement

The statements in this press release that are not historical statements, including statements regarding future financial performance, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks and uncertainties, many of which are beyond the company’s control that could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncertainties include, but are not limited to: the significant adverse impacts on economic and market conditions of the COVID-19 pandemic; the company’s ability to respond to the challenges and business disruption presented by the COVID-19 pandemic; the recent dislocation of the global energy market; the company’s ability to realize cost savings and efficiencies relating to the streamlining of its Energy Solutions business; the company’s ability to manage its liquidity; the company’s ability to continue to generate anticipated levels of revenue, profits and cash flow from operations during the COVID-19 pandemic and any resulting economic downturn; the outcome of and the publicity surrounding audits and investigations by domestic and foreign government agencies and legislative bodies; potential adverse proceedings by such agencies and potential adverse results and consequences from such proceedings; the scope and enforceability of the company’s indemnities from its former parent; changes in capital spending by the company’s customers, including as a result of the COVID-19 pandemic; the company’s ability to obtain contracts from existing and new customers and perform under those contracts; structural changes in the industries in which the company operates; escalating costs associated with and the performance of fixed-fee projects and the company’s ability to control its cost under its contracts; claims negotiations and contract disputes with the company’s customers; changes in the demand for or price of oil and/or natural gas; protection of intellectual property rights; compliance with environmental laws; changes in government regulations and regulatory requirements; compliance with laws related to income taxes; unsettled political conditions, war and the effects of terrorism; foreign operations and foreign exchange rates and controls; the development and installation of financial systems; increased competition for employees; the ability to successfully complete and integrate acquisitions; and operations of joint ventures, including joint ventures that are not controlled by the company.

KBR’s most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks, and other U.S. Securities and Exchange Commission filings discuss some of the important risk factors that KBR has identified that may affect the business, results of operations and financial condition. Except as required by law, KBR undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/kbr-charity-golf-tournament-raises-over-530k-gives-back-to-covid-19-frontline-workers-301178469.html

SOURCE KBR, Inc.

The Michigan Moonshot Partners with Toyota and Cisco to Expand Wi-Fi Access in Detroit, Inkster, Flint and Washtenaw County, Michigan

Free Wi-Fi Added at 50 Public Sites

PR Newswire

ANN ARBOR, Mich., Nov. 23, 2020 /PRNewswire/ — Residents of Detroit, Inkster, Flint and Washtenaw County will soon benefit from expanded free Wi-Fi access at more than 50 community locations across S.E. Michigan. The effort, part of Merit Network’s Michigan Moonshot initiative, was supported by contributions from the Toyota USA Foundation and Cisco. Washtenaw Intermediate School District and Merit Network provided in-kind contributions for the project. 

According to the U.S. Census Bureau, Detroit Public Schools has the highest number of households in the state without internet access at 82,894. The Flint School District has the second highest number with 14,221 households without internet access. In addition, 57% of K-12 students in Washtenaw County do not have high speed Wi-Fi access at home. 

“For thousands of students across the state of Michigan, the pandemic has introduced new challenges or highlighted existing ones,” said Charlotte Bewersdorff, Merit Network’s vice president for Community Engagement. “We expect this to help both rural and urban communities access the internet for basic informational needs tied to living, learning and working.”

The grants address the digital divide by providing community organizations with the technological ability to extend their existing internet connectivity through Wi-Fi networks which are accessible outside the buildings. Detroit Public Library will extend their Wi-Fi network beyond the walls of nine select sites, during normal business hours. Washtenaw Intermediate School District is coordinating 30 different access points at area schools and community partners across the county.

“As COVID-19 continues to spread throughout our nation, Toyota is proud to partner with Michigan Moonshot and Cisco to expand free Wi-Fi to Southeast Michigan area schools, libraries and community gathering locations to provide an immediate solution to this urgent issue of access,” said Chris Reynolds, chief administrative officer, Toyota Motor North America.

Beyond Washtenaw County where Toyota has its North American research and development headquarters, the Toyota USA Foundation provided grants to help address the digital divide in 13 states across the nation. 

Internet access at community sites is powered and secured by Cisco’s next-generation Wi-Fi and cloud security technology. The overall effort is supported through Cisco’s Country Digital Acceleration (CDA) program, which has over 900 active or completed mass-scale digitization projects in 37 countries around the world.

“It is our responsibility as business leaders to step up and mobilize the tools and innovations at our disposal to help curtail the growing disparities in our communities caused by the digital divide,” said Nick Michaelides, senior vice president, U.S. Public Sector at Cisco. “We are proud to launch this initiative alongside Merit and Toyota to help ensure equity of access, and to power an inclusive future for all Michiganders.”

Moving into the future, the Michigan Moonshot will continue to identify and lessen the impacts of inequitable access to broadband internet with the help from our communities. If your community, private or philanthropic organization is interested in supporting local Community Access Network sites, please contact [email protected]

To view an interactive map of all locations and hours of operation, please visit MichiganMoonshot.org/CommunityWiFi

ABOUT THE MICHIGAN MOONSHOT

The Michigan Moonshot is a collective call to action which aims to bridge the digital divide in Michigan. Stakeholders include Merit Network, the nation’s longest-running research and education network, the Quello Center at Michigan State University and M-Lab, the largest open internet measurement platform in the world. This call to action is an initiative to expand broadband access to all citizens through policy and funding, data and mapping, education and resources. Learn more about the Michigan Moonshot at Merit.edu/moonshot.

ABOUT MERIT NETWORK

Merit Network, Inc. is a nonprofit corporation owned and governed by Michigan’s public universities. Merit owns and operates America’s longest-running regional research and education network. In 1966, Michigan’s public universities created Merit as a shared resource to help meet their common need for networking assistance. Since its formation, Merit Network has remained at the forefront of research and education networking expertise and services. Merit provides high-performance networking and IT solutions to Michigan’s public universities, colleges, K-12 organizations, libraries, state government, healthcare, and other non-profit organizations. For more information: www.merit.edu.

ABOUT CISCO

Cisco is the worldwide leader in technology that powers the Internet. Cisco inspires new possibilities by reimagining your applications, securing your data, transforming your infrastructure, and empowering your teams for a global and inclusive future. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

ABOUT TOYOTA

Toyota (NYSE:TM) has been a part of the cultural fabric in North America for more than 60 years, and is committed to advancing sustainable, next-generation mobility through our Toyota and Lexus brands plus our 1,800 dealerships. 

Toyota has created a tremendous value chain and directly employs more than 47,000 in North America. The company has contributed world-class design, engineering, and assembly of more than 40 million cars and trucks at our 14 manufacturing plants, 15 including our joint venture in Alabama that begins production in 2021.

The Toyota USA Foundation is a charitable endowment created to support education programs serving kindergarten through 12th-grade students and their teachers in the United States, with an emphasis on science, technology, engineering, and math (STEM).  For more information about the Toyota USA Foundation, visit


www.toyota.com/foundation.

ABOUT WASHTENAW INTERMEDIATE SCHOOL DISTRICT

Washtenaw Intermediate School District (WISD) is the educational service agency for Washtenaw County, Michigan, serving nine public school districts and the public school academies in the greater Ann Arbor region. WISD provides an array of services to the community and local schools, including: special education leadership and coordination, early childhood services, technology support, business and human resources assistance, cradle-to-career community partnerships, and teacher and staff professional development.  For more information, visit www.washtenawisd.org.

For more information:
MichiganMoonshot.org/CommunityWiFi

MEDIA CONTACT

Media Relations Contact

Praveena Ramaswami

[email protected]

Pierrette Renée Dagg
(937) 212-0631

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/the-michigan-moonshot-partners-with-toyota-and-cisco-to-expand-wi-fi-access-in-detroit-inkster-flint-and-washtenaw-county-michigan-301178443.html

SOURCE Toyota Motor North America

Carvana Launches in Harrisonburg with As-Soon-As-Next Day Delivery

Carvana Launches in Harrisonburg with As-Soon-As-Next Day Delivery

Leading Online Auto Retailer Expands to its Third Market in the Shenandoah Valley

HARRISONBURG, Va.–(BUSINESS WIRE)–Carvana (NYSE: CVNA), a leading e-commerce platform for buying and selling used cars, is now offering as-soon-as-next-day touchless home delivery to Harrisonburg area residents. In as little as five minutes, customers can shop more than 20,000 vehicles, finance, purchase, trade in, and schedule as-soon-as-next-day vehicle delivery. Customers can also sell their current vehicle to Carvana and receive a real offer in just minutes—even without purchasing a vehicle.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201123005424/en/

Carvana brings The New Way to Buy a Car® to Harrisonburg, Va., offering as-soon-as-next-day vehicle delivery to its 263rd market. (Photo: Business Wire)

Carvana brings The New Way to Buy a Car® to Harrisonburg, Va., offering as-soon-as-next-day vehicle delivery to its 263rd market. (Photo: Business Wire)

Carvana customers shop online from the comfort of home or on the go via their mobile device, saving valuable time and money by skipping the dealership entirely. All Carvana vehicles come with a 7-day return policy – an upgrade to the traditional test-drive – ensuring customers have time to determine if the vehicle fits their life. By living with their vehicle for a week, Harrisonburg residents can do everything from installing the bike rack for their next trip to the Shenandoah Valley bike trails or check if there’s enough cargo space for groceries.

Carvana pioneered online car buying, including its patented 360-degree virtual vehicle tour, where customers can view vehicles in high-definition, 360-degree photography, inside and out. Carvana vehicles are Carvana Certified, having passed a rigorous 150-point inspection, have never been in a reported accident and have no frame damage. Features, imperfections and updated information about open safety recalls are listed on every car’s vehicle description page.

“Harrisonburg residents will now be able to choose from thousands of vehicles online and have it delivered to their front door as soon as the next day,” said Ernie Garcia, Carvana founder and CEO. “An easy, convenient and transparent car buying experience is an offering we’re confident the community will embrace.”

Carvana now offers as-soon-as-next-day vehicle delivery to customers in 263 cities across the U.S.

About Carvana (NYSE: CVNA)

Founded in 2012 and based in Phoenix, Carvana’s (NYSE: CVNA) mission is to change the way people buy cars. By removing the traditional dealership infrastructure and replacing it with technology and exceptional customer service, Carvana offers consumers an intuitive and convenient online car buying and financing platform. Carvana.com enables consumers to quickly and easily shop more than 20,000 vehicles, finance, trade-in or sell their current vehicle to Carvana, sign contracts, and schedule as-soon-as-next-day delivery or pickup at one of Carvana’s patented, automated Car Vending Machines.

For further information on Carvana, please visit www.carvana.com, or connect with us on Facebook, Instagram or Twitter.

Carvana

Amy O’Hara

[email protected]

KEYWORDS: Arizona Virginia United States North America

INDUSTRY KEYWORDS: Other Consumer Technology Aftermarket Automotive General Automotive Internet Consumer Retail Online Retail

MEDIA:

Logo
Logo
Photo
Photo
Carvana brings The New Way to Buy a Car® to Harrisonburg, Va., offering as-soon-as-next-day vehicle delivery to its 263rd market. (Photo: Business Wire)

Moody’s Analytics Wins Climate Risk Award at Chartis RiskTech100®

Moody’s Analytics Wins Climate Risk Award at Chartis RiskTech100®

SAN FRANCISCO–(BUSINESS WIRE)–
Moody’s Analytics has won the Climate Risk category in the 2021 Chartis RiskTech100®, the first year this category has appeared. It’s one of 10 awards for Moody’s Analytics to go along with the #2 overall ranking.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201123005378/en/

The Moody’s Analytics offering helps customers first identify whether they have exposureto climate risk in their portfolios and then quantify the impactof exposure to various climate risk factors.

“Expanding our climate risk capabilities is a top priority and one we have invested significantly in achieving,” said Dr. Jing Zhang, Managing Director and Global Head of Quantitative Research at Moody’s Analytics. “Severe climate events throughout 2020 underscore the importance and urgency for market participants to understand how climate change is already affecting—and will continue to affect—the risk and return of their portfolios.”

Measuring the physical risks associated with climate change is one piece of the climate risk management puzzle. Award-winning climate risk analytics from Moody’s ESG Solutions, powered by Moody’s affiliate Four Twenty Seven, a leading provider of physical climate risk data and V.E, a Moody’s affiliate with expertise in transition risk, ESG, and corporate disclosures, are being incorporated across Moody’s Analytics solutions. Moody’s climate solutions suite brings climate data into risk management tools, translating climate risk exposure into financial impact and credit risk across asset classes.

Our team recently conducted an AI-powered study of climate-related disclosures from roughly 12,000 companies, across industries and regions. Among the findings, which were presented to the Task Force on Climate-Related Financial Disclosures (TCFD) and are highlighted in the most recent status report on TCFD implementation: Only 17% of the companies examined had reported any climate-related information, and with significant variation in focus, content, and quality.

Capabilities from Moody’s ESG Solutions are also increasingly being leveraged by Moody’s Investors Service (the credit rating agency and sister company of Moody’s Analytics).

Moody’s Analytics, Moody’s, and all other names, logos, and icons identifying Moody’s Analytics and/or its products and services are trademarks of Moody’s Analytics, Inc. or its affiliates. Third-party trademarks referenced herein are the property of their respective owners.

About Moody’s Analytics

Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter and LinkedIn.

Moody’s Analytics, Inc. is a subsidiary of Moody’s Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.8 billion in 2019, employs approximately 11,400 people worldwide and maintains a presence in more than 40 countries.

JUSTIN BURSZTEIN

Moody’s Analytics Communications

+1.212.553.1163

Moody’s Analytics Media Relations

moodysanalytics.com

twitter.com/moodysanalytics

linkedin.com/company/moodysanalytics

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Professional Services Data Management Environment Technology Insurance Software Finance

MEDIA:

Logo
Logo
Logo
Logo

Texas Mineral Resources Adds Senior Mining Executive Kevin Francis to Board of Directors in Support of Planned Expansion Strategic Initiatives

SIERRA BLANCA, TX, Nov. 23, 2020 (GLOBE NEWSWIRE) — via NewMediaWire – Texas Mineral Resources Corp. (OTCQB: TMRC)

  • Senior mining executive with over thirty-two years of technical services, mine operations management, project development, re-engineering and leadership experience
  • Additional domestic mining projects projected to be added to TMRC portfolio

Texas Mineral Resources Corp. (TMRC), an exploration company currently targeting the heavy rare earths, technology metals and a variety of industrial minerals primarily through its Round Top Mountain project in Texas along with its funding and development partner, USA Rare Earth LLC, is pleased to announce the addition of Kevin Francis to its Board of Directors.

Mr. Francis is a broadly experienced mining professional who has been working in the industry for more than 32 years. Mr. Francis has held many senior executive and advisory roles within the mining industry, including Vice President of Project Development for Aurcana Silver Corporation, Vice President of Technical Services for Oracle Mining Corporation, Vice President of Resources for NovaGold Resources and Principal Geologist for AMEC Mining and Metals. Mr. Francis is currently Principal of Mineral Resource Management, a mining consultancy focused on providing technical leadership to the mining and exploration industry. Mr. Francis is a “qualified person” as defined by SEC S-K 1300 and Canadian NI 43-101 reporting standards. Mr. Francis holds both an M.S. degree and a B.A. in geology from the University of Colorado.

“Kevin’s unique set of skills will be instrumental as TMRC anticipates expanding its business to include other domestic mining projects to its portfolio with return potential similar to its current Round Top heavy rare earth and critical mineral project,” commented Anthony Marchese, Chairman. “Kevin’s decades of experience and mining industry expertise in traditional metals fits perfectly with the objectives of the Company.”

Dan Gorski, TMRC’s Chief Executive officer commented: “We are privileged to have Kevin serve as an active member of our board. TMRC believes the supply and demand fundamentals for a variety of commodities in view of worldwide geopolitics call for a reexamination of domestic mineral potential. Having Kevin join us is a significant step in this endeavor.”


About Texas Mineral Resources Corp.

Texas Mineral Resources Corp.’s focus is to develop and commercialize, along with its funding and development partner USA Rare Earth LLC,  its Round Top heavy-rare earth, technology metals, and industrial minerals project located in Hudspeth County, Texas, 85 miles southeast of El Paso. Additionally, the Company plans on developing alternative sources of strategic minerals through the processing of coal waste and other related materials as well as developing other domestic mining projects in more traditional metals.  The Company’s common stock trades on the OTCQB U.S. tier under the symbol “TMRC.”

Company Contact:

Texas Mineral Resources Corp.
Anthony Marchese, Chairman
E-mail: [email protected]
Twitter: @TexasMineralRes



Anthem Study Shows Majority of Employers Experiencing Value of Integrating Their Employee Benefits Portfolio

Anthem Study Shows Majority of Employers Experiencing Value of Integrating Their Employee Benefits Portfolio

The 2020 findings show integrated health care has become the norm amongst employers

INDIANAPOLIS–(BUSINESS WIRE)–
A recent study by Anthem shows a trend over the last several years is here to stay as the majority of employers are integrating healthcare benefits to create a more efficient, effective and affordable benefits package for their employees.

The recently published fourth edition of the biennial “Integrated Health Care Report,” shows a continued upward trajectory in the adoption of integrated health care benefits by employers since research began in 2014. More than half (56 percent) of the 300 employers surveyed are now actively integrating their medical, pharmacy and ancillary benefits under their employer’s health and wellness programs. This represents a 10 percent increase from the previous study conducted in 2018. Also, an additional 40 percent are considering or potentially considering integrating benefits, demonstrating that an overwhelming 96 percent of employers surveyed are trending towards the integrated health care approach.

“At Anthem, we’re committed to improving lives and communities, which takes an integrated ‘whole person health’ approach where doctors, data, analytics, insights and member engagement tools work together to create better health outcomes. I’m optimistic that as more employers continue implementing integrated health benefits, we will continue seeing healthier and happier employees,” said Jeff Spahr, vice president, Specialty Business Development, Anthem. “Factoring in ‘whole person health’ helps us better identify and share information, and create opportunities that will positively and proactively impact employees’ overall wellbeing, simplify their health care experience and lower their health care costs.”

The Anthem study demonstrates that delivering medical, pharmacy, dental, vision and disability as individual benefits with little-to-no coordination between them prevents employees and health care providers from gaining a holistic view of total body health. When using an integrated health care approach, benefits data is connected to the employer’s health management program and establishes a fuller picture of a person’s health, which provides a clear path to improved outcomes and cost efficiencies.

The report found that among employers who are actively integrating products, the majority of them reported integrating pharmacy (73 percent), vision (75 percent), dental (67 percent) and / or disability (63 percent) benefits with medical. The integration of pharmacy, vision and dental all saw increases of at least six percent over the findings of the previous study in 2018.

Affordability, simplicity and employee health remain key motivators for employers, but providing a simpler healthcare experience, as a reason for integrating health benefits, continues to trend upward. In fact, the top three most important integrated care capabilities cited by employers include connecting all doctors ­­ including eye doctors and dentists through electronic health records (EHR). Seventy-one percent of employers also preferred integrating benefits through a single carrier vs. multiple carriers, which represents an 11 percent jump since 2018.

To further improve the employee health journey, 88 percentof employers agree benefit offerings should be personalized to the individual, while 92 percentrecognized that increased digital capabilities are an important step in engaging employees in their health.

In addition to increased efficiency, lower costs and better care coordination, employers want to ensure their benefit offerings are as comprehensive and easy to use for employees as possible in an effort to keep them happy and engaged. That’s why 89 percent of employers report that increased employee happiness leads to increased productivity.

“It’s encouraging that employers are realizing employee health and benefits can impact their company beyond the associated health care costs, and can really speak to the bottom line,” said Spahr. “Offering employees a cost effective solution that integrates medical care with pharmacy, dental, vision, disability and other benefits programs will provide them with the personalized support they need to improve their overall wellbeing, satisfaction and productivity.”

Results from the study and more information can be found online in the Integrated Health Care Report.

The report was compiled from a study conducted by TRC Insights, an independent research firm, on behalf of Anthem, Inc. The four waves of research were conducted in 2014, 2016, 2018and 2020. This 2020 report was fielded in April 2020.

About Anthem, Inc.

Anthem is a leading health benefits company dedicated to improving lives and communities, and making healthcare simpler. Through its affiliated companies, Anthem serves more than 107 million people, including approximately 43 million within its family of health plans. We aim to be the most innovative, valuable and inclusive partner. For more information, please visit www.antheminc.com or follow @AnthemInc on Twitter.

Anthem, Inc. Media Contact

Keith Paulsen, (917) 993-1710

[email protected]

KEYWORDS: Indiana United States North America

INDUSTRY KEYWORDS: Insurance Human Resources Healthcare Reform Practice Management Pharmaceutical Optical General Health Professional Services Women Public Policy/Government Men Fitness & Nutrition Dental Family Consumer Health

MEDIA:

CytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97 Patients in the Next Few Weeks to Complete the Trial This Year

Concurrently,
CytoDyn
is
w
orking
d
iligently with the FDA to
initiate
its
Phase 2
COVID-19
Long Hauler
T
rial
, with m
ore than 100 volu
n
teers
wanting to enroll

VANCOUVER, Washington, Nov. 23, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has reached enrollment of 293 patients in its Phase 3 trial for COVID-19 patients with severe-to-critical symptoms, thereby meeting the requested criteria for a second interim efficacy analysis by the Data Safety Monitoring Committee (DSMC).

After the first interim analysis, the DSMC requested a second interim analysis of all data after enrollment had reached 293 patients or 75% of the total patients for the trial. Approximately five weeks ago, the DSMC completed the first interim analysis on 195 patients (or 50% of the 390 planned patients) and recommended the trial continue without modification to achieve the primary endpoint and requested another interim analysis when enrollment reached 75% level (or 293 patients) to review patient mortality and other clinical outcome data.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “In addition to filing our biologics license applications in Canada and the U.K. for HIV, the Company is in full swing to obtain full enrollment in the Phase 3 COVID-19 trial before year end and initiate our Phase 2 trial for COVID-19 patients with multiple long-hauler symptoms and perhaps complete enrollment in 4-6 weeks. On another front, CytoDyn is also about to enroll its first patient in the NASH trial this month. We are very appreciative of the all-out effort by our clinical operations team (especially Mr. Brian Brothen, the Company’s SVP of Global Oncology, and Dr. Kush Dhody from Amarex) and the clinical sites to expedite enrollment in this important trial and are hopeful the DSMC can complete their second interim analysis as quickly as possible. We continue to advance enrollment, without any pause to achieve the trial’s planned 390 patients and we are currently evaluating the ability to conduct an interim analysis as soon as possible. In the meantime, if the pace of enrollment we have experienced in the last two weeks continues, we will have the CD12 enrollment completed before the end of the year. These are exciting times for the Company and I am honored to be working alongside such dedicated co-workers.”     

About Coronavirus Disease 2019

CytoDyn completed its Phase 2 clinical trial (CD10) for COVID-19, a double-blinded, randomized clinical trial for mild-to-moderate patients in the U.S. which produced statistically significant results for NEWS2. Enrollment continues in its Phase 2b/3 randomized clinical trial for the severe-to-critically ill COVID-19 population in several hospitals and clinics throughout the U.S., which are identified on the Company’s website under the “Clinical Trial Enrollment” section of the homepage; an interim analysis on the first 195 patients was conducted mid-October and is expected to occur again now that the Company has reached enrollment of 293 patients.

About Leronlimab (PRO 140)

The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first indication is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients). 

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use. 

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.  

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD. 

About CytoDyn

CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH.

CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. The FDA met telephonically with Company key personnel and its clinical research organization and provided written responses to the Company’s questions concerning its recent Biologics License Application (“BLA”) for this HIV combination therapy in order to expedite the resubmission of its BLA filing for this indication.

CytoDyn has completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than six years.

CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com

Forward-Looking Statements 

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict.  Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company’s cash position, (ii) the Company’s ability to raise additional capital to fund its operations, (iii) the Company’s ability to meet its debt obligations, if any, (iv) the Company’s ability to enter into partnership or licensing arrangements with third parties, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company’s clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CONTACTS

Investors:

Michael Mulholland
Office: 360.980.8524, ext. 102
[email protected]



Consumer Resilience Shows Promise for 2021 Forecast


  • L


    ower


    delinquency rates


    and


    balance


    paydown


    demonstrate consumer resiliency

  • Lockdowns have impacted new credit growth


    for all products

  • Mortgages seem to be on a path of recovery due to pent-up demand and


    low





    interest rates

  • Slow growth in balances and m


    inimal


    increase


    in delinquencies


    forecasted


    for 2021

TORONTO, Nov. 23, 2020 (GLOBE NEWSWIRE) — The latest Q3 2020 TransUnion Industry Insights Report found that Canadian consumers have adapted well to the ongoing economic crisis spurred by the pandemic, showing signs of resiliency. While consumer spending habits have yet to revert to pre-pandemic levels, delinquency rates continue trending downward and some credit markets, such as mortgages, are seeing an influx of new activity and improved performance.

“Over the summer we saw early signs that Canadian consumers were adapting to the new economic environment,” said Matt Fabian, director of financial services research and consulting at TransUnion. “While many Canadians remain cautious with their spending, there are early signs of recovery, particularly when noting an increase in the funding of major purchases such as homes and cars.”

Further, TransUnion’s 2021 forecast indicates market stabilization, with slight increases to delinquencies as government relief programs and payment holidays expire.

Consumers
deleveraging to build resiliency

Several metrics point to Canadian credit-active consumers managing the impacts of the pandemic relatively well. Average non-mortgage consumer debt in Q3 3020 fell 4.2% from the prior year to $29,376 as consumers were active in paying down credit obligations. This drop was led by credit card balances, which declined by 11.6%. The decrease in credit card balances was partly due to lower spending and higher repayment activity. Public health measures to contain the COVID-19 pandemic resulted in a series of business closures, which reduced consumers’ ability to spend. Further, a recent Financial Hardship Survey by TransUnion from September 2020 revealed that many consumers deferred major purchases on credit cards, with 48% of consumers having delayed vacations due to travel restrictions.

Auto loan and line of credit total balances also decreased by 2.9% and 4.3%, respectively. Conversely, personal loan and mortgage balances increased by 4.2% and 5.6%, respectively. Mortgages, in particular, experienced higher growth and demand largely due to higher housing prices, which increased new mortgage average balances, and extremely low-interest rates benefitting refinance activity.

While unemployment rates reached their highest levels in a generation, the combination of government subsidies and payment holidays from most lenders supported consumers and helped manage cash flows during the pandemic. TransUnion’s September Financial Hardship Survey indicated that 48% of Canadian households reported experiencing negative financial impacts from COVID-19, down from a peak of 63% in April. Additionally, while just under half of the respondents reported a negative impact, 82% of consumers said their household finances were planned for the rest of 2020, with 43% indicating their finances were better than anticipated.

New credit growth slowing down

The unprecedented global nature of COVID-19 severely impacted the volume of new credit originations. New account openings were down 41% in Q2 2020—the most recent quarter for which originations data are available due to the reporting lag—as a result of lower consumer demand and lenders curtailing originations to mitigate unexpected risk. As lockdowns tightened and the economy worsened, lenders tightened risk and lending policies which have impacted new credit supply.

The largest decline was observed in credit card originations, where volumes were down 63% from the prior year. Auto loans also declined YoY by 38% due to reduced consumer demand and lockdowns that closed dealerships.

Amongst all credit products, mortgages experienced the lowest YoY decline of 2.2% in Q2 2020, as low-interest rates encouraged refinancing and as pent-up demand from the early spring lockdowns was released at the end of the second quarter when certain regional restrictions eased. “In the coming months, we expect slower origination volumes even as restrictions ease because lenders will continue to manage and mitigate risk,” added Fabian.

Credit Products Q2 2020
YoY change in origination volume
BankCard -63.0%
Auto Loan -38.0%
Line of Credit -43.4%
Installment -33.1%
Mortgage -2.2%

G
overnment subsidies and payment holidays support
ing
low delinquency trends

Delinquency rates remained low as consumers continued to take advantage of payment holidays on outstanding balances. Approximately 3.1 million Canadians have taken advantage of payment deferrals since the onset of the pandemic, a proactive treatment strategy executed by lenders to support consumers through record-high unemployment and financial hardship.

Consumers have used the excess cash made available by these payment holidays to pay down outstanding bills or debt, and in some cases have continued to pay down balances against products on which they have taken a deferral. As a result, Canada’s overall non-mortgage consumer-level delinquency rate fell 48 basis points to 1.44% in Q3 2020 from the prior year.

“Canadians have leveraged government programs and lender support to offset cash flow concerns as both the government and lenders continued to support consumers through this economic shock. This has helped keep delinquency rates at low levels,” explained Fabian. “Nevertheless, we do anticipate an increase in delinquency rates next year as deferral options expire and some consumers struggle to maintain payments due to financial impacts caused by a prolonged pandemic.”

Outlook calls for performance stabilization in 2021

TransUnion’s updated Canadian credit market forecast indicates continued consumer deleveraging and muted originations levels, which are both expected to result in a decline in outstanding balances by the end of 2020 for major credit products. TransUnion projects a 2% YoY drop in non-mortgage balances by the end of 2020, and expects a stabilization in 2021 with a slight 0.2% increase by the end of the year. As the government subsidies end, impacted consumers will experience income shocks and may have reduced liquidity to meet debt obligations. TransUnion anticipates an increase in overall consumer delinquency rates into 2021, with non-mortgage consumer delinquency increasing by 9 bps after a large drop in 2020.

The forecast suggests a slight increase in delinquencies for credit cards and mortgages. “While mortgage delinquency rates are forecasted to increase in 2020 and 2021, it is important to remember that rates are already relatively low at under one percent, so we expect they will remain at manageable levels through 2021. From an origination perspective, our forecast calls for continued low volumes through 2020, but a rebound for cards and continued demand for mortgages in 2021,” said Fabian.

Monthly & A
t
the end of DEC

Originations Average Consumer
Balances
Consumer
Delinquency (90+ DPD)
2019 YE 2020 YE 2021 YE 2019 YE 2020 YE 2021 YE 2019 YE 2020 YE 2021 YE
Non-Mortgage –  $30,287 $29,643 $29,691 1.93% 1.42% 1.51%
Credit Card 522,642 440,569 457,136 $4,245 $3,701 $3,487 0.90% 0.60% 0.66%
Mortgage 85,696 81,186 88,732 $277,152 $291,712 $307,337 0.18% 0.19% 0.20%
Installment 272,521 272,941 267,558 $35,605 $37,433 $37,839 0.98% 0.87% 0.91%
Auto Loan 84,993 77,976 71,425 $21,503 $21,489 $21,804 0.23% 0.21% 0.22%

About
TransUnion
(NYSE: TRU)

TransUnion is a global information and insights company that makes trust possible in the modern economy. We do this by providing a comprehensive picture of each person so they can be reliably and safely represented in the marketplace. As a result, businesses and consumers can transact with confidence and achieve great things. We call this Information for Good.® TransUnion provides solutions that help create economic opportunity, great experiences and personal empowerment for hundreds of millions of people in more than 30 countries. Our customers in Canada comprise some of the nation’s largest banks and card issuers, and TransUnion is a major credit reporting, fraud, and analytics solutions provider across the finance, retail, telecommunications, utilities, government and insurance sectors.

For more information or to request an interview, contact:
Contact

E-mail

Telephone
Fiona Bang
[email protected]
647-680-2885